Management of Obesity in Adults: European Clinical Practice GuidelinesTsigos C.a · Hainer V.b · Basdevant A.c · Finer N.d · Fried M.e · Mathus-Vliegen E.f · Micic D.g · Maislos M.h · Roman G.i · Schutz Y.j · Toplak H.k · Zahorska-Markiewicz B.l
for the Obesity Management Task Force of the European Association for the Study of Obesity a Endocrinology, Metabolism and Diabetes Unit, Evgenidion Hospital, Athens University Medical School, Athens, Greece bObesity Management Centre, Institute of Endocrinology, Prague, Czech Republic c Department of Endocrinology, Pitié Salpêtrière Hospital; Pierre and Marie Curie-Paris 6 University, Paris, France dInstitute for Metabolic Sciences, Univeristy of Cambridge School of Clinical Medicine, Cambridge, UK e Clinical Center for Minimally Invasive and Bariatric Surgery, ISCARE-Lighthouse, Prague and 1st Medical Faculty, Charles University, Prague, Czech Republic; representative of the International Federation for the Surgery of Obesity – European Chapter f Department of Gastroenterology and Hepatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands gCenter for Metabolic Disorders in Endocrinology, Institute of Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of Serbia, Belgrade, Serbia hAtherosclerosis and Metabolism Unit, Soroka UMC, Ben-Gurion University SHC, Beer Sheva, Israel i Clinical Center of Diabetes, Nutrition, Metabolic diseases, ‘Iuliu Hatieganu’ University, Cluj-Napoca, Romania j Department of Physiology, University of Lausanne, Lausanne, Switzerland k Department of Medicine, Institute for Diabetes and Metabolism, Medical University, Graz, Austria l Department of Pathophysiology, Medical University of Silesia, Katowice, Poland
Constantine Tsigos,MD, PhD, 82, Vass. Sophias Ave., 115 28 Athens, Greece, Tel. +30 210 74800-09, Fax -10, E-mail email@example.com
Do you have an account?
The development of consensus guidelines for obesity is complex. It involves recommending both treatment interventions and interventions related to screening and prevention. With so many publications and claims, and with the awareness that success for the individual is short-lived, many find it difficult to know what action is appropriate in the management of obesity. Furthermore, the significant variation in existing service provision both within countries as well as across the regions of Europe makes a standardised approach, even if evidence-based, difficult to implement. In formulating these guidelines, we have attempted to use an evidence-based approach while allowing flexibility for the practicing clinician in domains where evidence is currently lacking and ensuring that in treatment there is recognition of clinical judgment and of regional diversity as well as the necessity of an agreed approach by the individual and family. We conclude that i) physicians have a responsibility to recognise obesity as a disease and help obese patients with appropriate prevention and treatment, ii) treatment should be based on good clinical care and evidence-based interventions and iii) obesity treatment should focus on realistic goals and lifelong management.
© 2008 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.